Quantcast

A big deal in baby tests: Natera sets terms for $100 million IPO


Shutterstock photo

Natera, which sells non-invasive prenatal DNA tests, announced terms for its IPO on Monday.

The San Carlos, CA-based company plans to raise $100 million by offering 6.3 million shares at a price range of $15 to $17. At the midpoint of the proposed range, Natera would command a fully diluted market value of $848 million.

Natera, which was founded in 2003 and booked $179 million in sales for the 12 months ended March 31, 2015, plans to list on the NASDAQ under the symbol NTRA. Morgan Stanley, Cowen & Company and Piper Jaffray are the joint bookrunners on the deal. It is expected to price during the week of June 29, 2015.

The article A big deal in baby tests: Natera sets terms for $100 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO) or the Global IPO Fund (symbol: IPOSX) , may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs



More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs










Research Brokers before you trade

Want to trade FX?